Sutton Wealth Advisors’s Royalty Pharma RPRX Stock Holding History

Sutton Wealth Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-32	Closed	-$1.15K	–	867
2023 Q1	$1.15K	Hold	32	–	–	﹤0.01%	714
2022 Q4	$1.26K	Hold	32	–	–	﹤0.01%	1269
2022 Q3	$1.29K	Hold	32	–	–	﹤0.01%	1241
2022 Q2	$1.34K	Hold	32	–	–	﹤0.01%	1229
2022 Q1	$1.25K	Hold	32	–	–	﹤0.01%	1283
2021 Q4	$1.27K	Buy	+32	New	+$1.24K	﹤0.01%	1270

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sutton Wealth Advisors's RPRX Position: Q2 2023 in Review

Sutton Wealth Advisors sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 32 shares — an estimated $1.15K sold.

Sutton Wealth Advisors first reported a position in RPRX in Q4 2021 and held it in 6 quarters. The position peaked at $1.34K in Q2 2022. 326 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

Sutton Wealth Advisors reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
Sutton Wealth Advisors sold 32 Royalty Pharma shares in Q2 2023, an estimated $1.15K.
Sutton Wealth Advisors first reported a position in Royalty Pharma in Q4 2021 and held it in 6 quarters.
Sutton Wealth Advisors's Royalty Pharma position peaked at $1.34K in Q2 2022.
326 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on Sutton Wealth Advisors's 13F filing for Q2 2023, filed 8 Nov 2023.